好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Exosomes From MS Patient Serum Carry EBV Early Antigens not Detected in Exosomes From Healthy Donor Patient Serum
Multiple Sclerosis
P2 - Poster Session 2 (11:45 AM-12:45 PM)
18-005
To characterize EBV latent and lytic protein contents in MS serum exosomes compared to healthy controls and assess for any relationships to disease activity.
Epstein-Barr Virus (EBV) has be shown to be key risk factor in the development of MS. However, the exact relationship to MS pathogenesis is still under investigation.  Prior work has focused on potential relationships between EBV latent proteins and MS disease activity. exosomes can play a role in the immune response.

We collected and stored MS and healthy control (HC) serum samples at -80C. We included 24 MS patients and 5 healthy controls within this study. Exosomes were isolated following initial filtration with 0.22um filter, using ExoQuick reagent (SBI). Samples were run on Western blot and probed for EBNA1, EBNA2A, Early antigen D (EaD), LMP1, LMP2A, BZLF, BHRF1. The presence or absence of antigen was assessed using ImageJ software.

Here, results for EBNA1, EaD and BZLF are presented. EBNA1 was detected in 23 of 24 MS serum samples and in all 5 healthy controls tested (Fisher exact test, p-value=1). EaD was detected in 7 of 24 MS serum samples tested but not detected in healthy controls (Fisher exact test, p-value=.1608). BZLF was detected in 7 of 21 MS serum exosome samples while 1 of 5 healthy controls exosomes carried it (Fisher exact test, p-value=.1414) Based on results, clinical evaluation was undertaken in patients positive for EaD, and for those which the information was recorded, EaD exosome detection was found to be detectable in samples drawn within 3 mos of flare, while those that were negative were at least 3 mos removed from a flare.

EaD, an early lytic protein of EBV, was only detected in exosomes from MS patients and appeared within a subset of patients whose samples were collected within 3 mos of flare.

Authors/Disclosures
Monique Anderson, MD, PhD (Mass General Hospital)
PRESENTER 		Dr. Anderson has nothing to disclose.
Fiona J. Salas Ms. Salas has nothing to disclose.
Natalia Drosu Ms. Drosu has nothing to disclose.
Philippe-Antoine Bilodeau, MD (Massachusetts General Hospital) Dr. Bilodeau has nothing to disclose.
Joao Vitor Mahler, MD Dr. Mahler has received research support from The Sumaira Foundation.
Mulan Jiang Ms. Jiang has nothing to disclose.
Takahisa Mikami, MD (Massachusetts General Hospital) Dr. Mikami has nothing to disclose.
Rebecca Salky Rebecca Salky has nothing to disclose.
James V. Nguyen, MD, MEd (Mass General Brigham) Dr. Nguyen has nothing to disclose.
Gabriela Romanow (Massachusetts General Hospital) Gabriela Romanow has nothing to disclose.
Michael Levy, MD, PhD, FAAN (Massachusetts General Hospital/Harvard Medical School) Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Pharma. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Pharma. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Levy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Levy has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Levy has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Various law firms. The institution of Dr. Levy has received research support from National Institutes Health.